Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > The QMN Weekly Bulletin > Minneapolis Biotechnology Plant Trades in $240 Million Deal

The QMN Weekly Bulletin

Feb. 29, 2008 | Vol. 2 No. 9

Minneapolis Biotechnology Plant Trades in $240 Million Deal

Dutch biopharmaceutical firm Genmab A/S has agreed to pay $240 million to acquire an antibody manufacturing facility owned by PDL BioPharma Inc. in suburban Minneapolis, Minn.
CoStar Group

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Arch Pharmalabs Looking at Takeovers in Europe Pfizer Ends a Long Chapter in Groton CRAMS Firm Gathers Momentum Glenmark Gets Shareholder Nod to Spin Off Generic Business

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.